Uji klinis PPOK di California
26 studi untuk PPOK mencari peserta di lokasi di California.
Kota di California
- Los Angeles9 studi
- Newport Beach8 studi
- San Francisco5 studi
- San Diego4 studi
- Long Beach3 studi
- Santa Clarita3 studi
- Buena Park3 studi
- Mountain View3 studi
Teks studi resmi (Bahasa Inggris)
A Study Evaluating the Efficacy of Budesonide, Glycopyrronium and Formoterol Fumarate Metered Dosed Inhaler on Cardiopulmonary Outcomes in Chronic Obstructive Pulmonary Disease
- Research Site, Castroville
- Research Site, Garden Grove
- Research Site, Inglewood
- dan 12 lainnya
Menerima pesertaFase 3
Usia 40 hingga 80 · Semua jenis kelamin · Diperbarui 2 Okt 2026 · NCT06283966Efficacy, Safety, and Tolerability Study of Lunsekimig Compared With Placebo in Adult Participants With Inadequately Controlled Chronic Obstructive Pulmonary Disease (COPD), Characterized by an Eosinophilic Phenotype
- Ark Clinical Research- Site Number : 8400113, Long Beach
- Inglewood Clinical- Site Number : 8400074, Los Angeles
- Alliance Clinical - West Hills- Site Number : 8400067, Los Angeles
- dan 2 lainnya
Menerima pesertaFase 3
Usia 40 hingga 80 · Semua jenis kelamin · Diperbarui 1 Okt 2026 · NCT07190222To Evaluate the Effect of EXPD-101/FXS7553 Compared With Placebo in Patients With COPD Over 52 Weeks of Treatment
- California Medical Research Associates Inc., Northridge
Menerima pesertaFase 2
Usia 40 hingga 85 · Semua jenis kelamin · Diperbarui 30 Sep 2026 · NCT07684820A Study of Brenipatide (LY3537031) in Adult Participants With Moderate-to-Severe Chronic Obstructive Pulmonary Disease (COPD)
- NewportNativeMD, Inc., Newport Beach
- Institute of HealthCare Assessment d/b/a Apex Clinical Research, San Diego
Menerima pesertaFase 2
Usia 40 hingga 75 · Semua jenis kelamin · Diperbarui 25 Sep 2026 · NCT07759245Efficacy, Safety, and Tolerability Study of Lunsekimig Compared With Placebo in Adult Participants With Inadequately Controlled Chronic Obstructive Pulmonary Disease (COPD) Characterized by an Eosinophilic Phenotype
- IMAX Clinical Trials- Site Number : 8400109, La Palma
- Long Beach Research Institute- Site Number : 8400027, Long Beach
- Downtown L.A. Research Center- Site Number : 8400009, Los Angeles
- dan 3 lainnya
Menerima pesertaFase 3
Usia 40 hingga 80 · Semua jenis kelamin · Diperbarui 22 Sep 2026 · NCT07190209A Study to Evaluate the Long-term Safety and Efficacy of Lunsekimig in Adult Participants With Chronic Obstructive Pulmonary Disease (COPD)
- Newport Native MD- Site Number : 8403003, Newport Beach
Menerima pesertaFase 3
Usia 40 hingga 80 · Semua jenis kelamin · Diperbarui 21 Sep 2026 · NCT07793409A Study of WIN378 in Participants With Moderate to Severe COPD (Sirius)
- WB Contracted Clinical Research Site, Los Angeles
Menerima pesertaFase 2
Usia 40 hingga 80 · Semua jenis kelamin · Diperbarui 15 Sep 2026 · NCT07646587A Study to Investigate the Effect of AZD6793 in Participants With Moderate to Very Severe Chronic Obstructive Pulmonary Disease
- Research Site, Los Angeles
- Research Site, Newport Beach
- Research Site, Norco
Menerima pesertaFase 2
Usia 40 ke atas · Semua jenis kelamin · Diperbarui 9 Sep 2026 · NCT07082738Clinical Trial of Omalizumab for Allergen Sensitized and Exposed Individuals With COPD
- University of San Francisco, San Francisco
Menerima pesertaFase 2
Usia 40 ke atas · Semua jenis kelamin · Diperbarui 4 Sep 2026 · NCT07059091A Study to Investigate the Efficacy and Safety of Tezepelumab in Adult Participants With Moderate to Very Severe COPD (D5241C00007)
- Research Site, Los Angeles
- Research Site, Palo Alto
Menerima pesertaFase 3
Usia 40 hingga 80 · Semua jenis kelamin · Diperbarui 3 Sep 2026 · NCT06878261A Study to Investigate the Efficacy and Safety of Tezepelumab in Adult Participants With Moderate to Very Severe COPD (D5241C00006)
- Research Site, Garden Grove
- Research Site, Newport Beach
- Research Site, Torrance
Menerima pesertaFase 3
Usia 40 hingga 80 · Semua jenis kelamin · Diperbarui 3 Sep 2026 · NCT06883305A Study to Test the Safety and Effects of Inhaled GDC-6988 in Participants With Muco-obstructive Disease
- Stanford Center for Excellence in Pulmonary Biology, Palo Alto
Menerima pesertaFase 1
Usia 18 ke atas · Semua jenis kelamin · Diperbarui 2 Sep 2026 · NCT06603246A Study to Learn About the Study Medicine Called PF-07275315 in People With Moderate to Severe Chronic Obstructive Pulmonary Disease
- IMAX Clinical Trials, La Palma
- NewportNativeMD, Inc., Newport Beach
- California Medical Research Associates, Northridge
- dan 1 lainnya
Menerima pesertaFase 2/3
Usia 35 hingga 80 · Semua jenis kelamin · Diperbarui 31 Agu 2026 · NCT07363694A Non-inferiority Pharmacokinetic and Safety/Tolerability Study of Two Different Doses of Weekly SC Alpha1-PI 15% Compared With Corresponding Standard IV Alpha1-PI in Participants With Alpha1-Antitrypsin Deficiency (AATD)
- GC2501 Study Site 100, Los Angelas
Menerima pesertaFase 3
Usia 18 hingga 80 · Semua jenis kelamin · Diperbarui 11 Agu 2026 · NCT07555483STRIVE Post-Market Registry Study
- El Camino, Taft Center for Clinical Research, Mountain View
Menerima pesertaStudi observasional
Usia 18 ke atas · Semua jenis kelamin · Diperbarui 3 Agu 2026 · NCT04302272Multi-Center Clean Air Randomized Controlled Trial in COPD
- University of California, Los Angeles, Los Angeles
Menerima pesertaFase 3
Usia 40 ke atas · Semua jenis kelamin · Diperbarui 31 Jul 2026 · NCT06376994eValuating the Efficacy and Safety of InitiatinG depemokImab earLy therApy iN Chronic Obstructive Pulmonary Disorder (COPD) With Type 2 Inflammation
- GSK Investigational Site, Newport Beach
Menerima pesertaFase 3
Usia 40 hingga 75 · Semua jenis kelamin · Diperbarui 28 Jul 2026 · NCT07177339Lung Macrophage Populations and Functions in Chronic Obstructive Pulmonary Disease (COPD)-Susceptible Smokers
- San Francisco VA Medical Center, San Francisco
Menerima pesertaStudi observasionalSukarelawan sehat diterima
Usia 40 hingga 75 · Semua jenis kelamin · Diperbarui 4 Jun 2026 · NCT04722835A Multi Center Study Testing a New Implant for Adults With Severe Emphysema
- University of California, San Francisco, San Francisco
Menerima peserta
Usia 22 ke atas · Semua jenis kelamin · Diperbarui 3 Jun 2026 · NCT07119229The Cardiovascular Consequences of Sleep Apnea Plus COPD (Overlap Syndrome)
- UCSD Sleep Research, La Jolla
Menerima pesertaFase 2
Usia 40 hingga 79 · Semua jenis kelamin · Diperbarui 3 Jun 2026 · NCT05237505SPIROMICS Study of Early COPD Progression (SOURCE)
- University of California Los Angeles, Los Angeles
- University of California, San Francisco, San Francisco
Menerima pesertaStudi observasionalSukarelawan sehat diterima
Usia 30 hingga 55 · Semua jenis kelamin · Diperbarui 3 Jun 2026 · NCT05033990Bronchoscopic RElease of Air Trapped in Hyperinflated Emphysematous Lung - Study 3
- University of California at Davis, Sacramento
Menerima peserta
Usia 40 hingga 84 · Semua jenis kelamin · Diperbarui 24 Apr 2026 · NCT06891755PiMZ Longitudinal Cohort (PiMZ Logic)
- University of California- Los Angeles, Los Angeles
Menerima pesertaStudi observasional
Usia 18 ke atas · Semua jenis kelamin · Diperbarui 16 Jan 2026 · NCT06505603Rehabilitation in Safety-net Environments (RISE) to Improve Outcomes in Vulnerable Patients With COPD
- Zuckerberg San Francisco General (ZSFG) Hospital, San Francisco
- Maxine Hall Health Center (MHHC), San Francisco
- Southeast Health Center (SEHC), San Francisco
Menerima peserta
Usia 40 hingga 90 · Semua jenis kelamin · Diperbarui 1 Des 2025 · NCT05572632Clinical Validation of Freenome Multiomics Blood Test for Lung Cancer Screening
- Science 37, Los Angeles
Menerima pesertaStudi observasional
Usia 50 ke atas · Semua jenis kelamin · Diperbarui 5 Agu 2025 · NCT06122077Site and Mechanism(s) of Expiratory Airflow Limitation in COPD, Emphysema and Asthma-COPD Overlap
- Arthur F Gelb MD, Lakewood
- Arthur F Gelb MD, Lakewood
Menerima pesertaStudi observasionalSukarelawan sehat diterima
Usia 30 ke atas · Semua jenis kelamin · Diperbarui 27 Okt 2023 · NCT03263130Dari ClinicalTrials.gov, data diambil 3 Okt 2026. Setiap studi menetapkan kriteria kelayakannya sendiri; tim studi yang menentukan siapa yang bisa bergabung.